A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.
Drake WM, Stiles CE, Bevan JS, Karavitaki N, Trainer PJ, Rees DA, Richardson TI, Baldeweg SE, Stojanovic N, Murray RD, Toogood AA, Martin NM, Vaidya B, Han TS, Steeds RP; UK Cabergoline valvulopathy study group; Baldeweg FC, Sheikh UE, Kyriakakis N, Parasuraman SK, Taylor L, Butt N, Anyiam S.
Drake WM, et al. Among authors: baldeweg fc, baldeweg se.
J Clin Endocrinol Metab. 2016 Nov;101(11):4189-4194. doi: 10.1210/jc.2016-2224. Epub 2016 Aug 29.
J Clin Endocrinol Metab. 2016.
PMID: 27571182